Jazz Pharmaceuticals (JAZZ) is drawing investor attention after outlining biomarker-driven approaches for HER2 expressing cancers such as gastroesophageal adenocarcinoma. The company is highlighting the limited existing options and quality of life pressures for these patients.
See our latest analysis for Jazz Pharmaceuticals.
Against this backdrop, Jazz Pharmaceuticals’ share price has eased 1.4% over the past day and 2.2% over the past month. It still shows a year to date share price return of 43.6% and a 1 year total shareholder return of 106.3%, which points to firm positive momentum around the stock as its HER2 focused pipeline progresses.
If this kind of biotech momentum has your attention, it could be worth scanning other healthcare companies that blend AI with drug development using the Simply Wall St 41 healthcare AI stocks.
After the recent share price pullback and a wide gap between Jazz Pharmaceuticals’ market price and valuation estimates, the real question now is where fair value actually falls within that range.
Most Popular Narrative: 11.6% Undervalued
The most followed narrative currently places Jazz Pharmaceuticals’ fair value at $281.35, above the last close of $248.70. This frames the recent pullback as a valuation gap rather than a completed move.
Ongoing investments in R&D, commercialization infrastructure, and international launches (such as rolling out Ziihera in BTC across Europe) are lowering barriers to entry in new geographies as healthcare access expands, positioning Jazz for steady long-term market share and revenue growth.
Curious what kind of revenue mix, margin profile, and future earnings multiple have to line up to support that fair value for Jazz Pharmaceuticals? The narrative focuses on rare-disease pricing power, a maturing neuroscience franchise, and oncology assets that need to scale internationally. The key is how those pieces are modeled to compound together over time.
Result: Fair Value of $281.35 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors also need to weigh risks for Jazz Pharmaceuticals, including potential generic pressure on sleep treatments and the possibility that key oncology trials or launches underperform relative to high expectations.
Find out about the key risks to this Jazz Pharmaceuticals narrative.
Another View on Jazz Pharmaceuticals Valuation
While the narrative fair value suggests Jazz Pharmaceuticals is 11.6% undervalued at $281.35 versus the current $248.70, the current 17.2x P/E is slightly higher than the 17x US pharmaceuticals industry average, yet below the 29.1x peer average and the 24.4x fair ratio. That mix points to both upside potential and valuation risk. Which side of that trade-off feels more convincing to you?
To unpack what these P/E gaps might mean in practice for future returns and downside risk, it helps to step through the valuation breakdown in more detail. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and concern around Jazz Pharmaceuticals resonates with you, do not wait to check the underlying numbers and sentiment yourself. To weigh both sides of the story in one place, review the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Jazz Pharmaceuticals?
If you are serious about putting this Jazz Pharmaceuticals research to work, do not stop at one stock. Use targeted stock lists to keep uncovering fresh opportunities.
- Supercharge your hunt for potential bargains by scanning companies that currently screen as 50 high quality undervalued stocks.
- Strengthen your focus on resilience by reviewing a curated set of 79 resilient stocks with low risk scores.
- Get ahead of the crowd by tracking a screener containing 19 high quality undiscovered gems that the market may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com